secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001725160-22-000163
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints Jan Skvarka as Class III director, cures Nasdaq listing compliance
--------------------------------------------------------------------------------

- Jan Skvarka, Ph.D., M.B.A., appointed as Class III director effective September 9, 2022.
- Appointment to Audit and Nominating Committees cures Nasdaq Listing Rule 5605(c)(2) non-compliance.
- Initial term expires at 2023 annual meeting; receives standard director compensation.
- Granted RSUs covering 36,606 shares (value ~$1M) vesting over three years.
- Also eligible for annual RSU grant (~$500k) and committee retainers ($10k audit, $5k nominating).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000163/0001725160-22-000163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000163/zntl-20220909.htm
  HTML page:      https://secwatch.observer/filing/0001725160-22-000163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer